At CD ComputaBio, we understand that immunogenicity assessment is critical in the development of biological drugs, including antibody therapeutics. Detecting and characterizing the immune response to these drugs is critical for patient safety, efficacy assessment, and regulatory compliance. Our team of experts has extensive experience in immunogenicity assessment and is committed to providing you with a comprehensive solution that meets your specific needs.
We specialize in developing and validating robust immunogenicity assays. Our team leverages our expertise in assay development and optimization to tailor assays for your specific drug and therapeutic targets. We ensure that our assays meet regulatory standards and provide accurate, reproducible results.
Our immunogenicity screening assays detect and quantify anti-drug antibodies (ADA) in patient samples. These assays help determine the presence and level of immune response to an antibody drug. We offer a variety of screening platforms, including ELISA, electrochemiluminescence (ECL), and surface plasmon resonance (SPR) technologies to accommodate different sample types and sensitivities.
Neutralizing antibodies (NAbs) can have a significant impact on the safety and efficacy of antibody drugs. Our neutralizing antibody assays are designed to evaluate the functional activity of NAbs and assess their impact on drug efficacy. By measuring the inhibitory effects of NAbs, we can provide insight into the potential clinical impact of the immune response.
Our Immunogenicity Risk Assessment service can help you assess the potential impact of immunogenicity on the safety and efficacy of your antibody drug. By integrating data from preclinical studies, in vitro assays, and clinical samples, we can provide comprehensive risk assessment reports. This allows you to make informed decisions about dosing regimens, patient monitoring and risk mitigation strategies.
Our advanced algorithms and bioinformatics tools enable accurate data analysis and interpretation. We provide detailed reports with comprehensive data summaries, statistical analyses, and clear visualizations of results. Our experts can guide you through the data interpretation process and provide valuable insights.
Our computational analysis employs a wide range of bioinformatics tools and databases to predict immunogenic hotspots, epitope mapping, and antigen presentation. This analysis helps identify potential risks and guide the optimization of drug candidates.
At CD ComputaBio, we are committed to providing accurate, reliable and customized solutions for antibody drug immunogenicity assessment. With our experienced team, state-of-the-art methods and advanced algorithms, we can ensure that you get high quality data and comprehensive reports. Partner with us to gain an in-depth understanding of your antibody drug's immunogenicity profile and make informed decisions during the drug development process.